Welcome to our dedicated page for IceCure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (NASDAQ: ICCM) reported expanding commercial adoption of its ProSense™ cryoablation system in Brazil following FDA marketing authorization for early-stage, low-risk breast cancer.
ProSense™ has ANVISA approval, commercial procedures are being performed in multiple tumor types, and two large independent breast cancer cryoablation studies (750 patients in Brazil, 900 in France) are underway or planned.
IceCure (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), which requires a bid price of at least $1.00 per share.
Nasdaq determined compliance after ICCM's closing bid met or exceeded $1.00 for 10 consecutive business days from June 4–17, 2026, and considers the bid price deficiency matter closed.
IceCure Medical (NASDAQ: ICCM) highlighted a peer-reviewed article in the International Journal of Surgery showing clinical advantages of ProSense cryoablation over radiofrequency ablation (RFA) for early-stage breast cancer.
The publication reports high local control rates comparable to breast-conserving surgery, notes a 99.02% recurrence-free rate in over 600 cryoablation patients, and describes procedural benefits such as local anesthesia and visible ice-ball margins. IceCure will present at the 34th Japanese Breast Cancer Society meeting on June 25-27, 2026, as partner Terumo plans a ProSense regulatory submission to Japan's PMDA in the second half of 2026.
IceCure (Nasdaq: ICCM) priced a $5.5 million private placement with a single healthcare-focused institutional investor at $3.00 per share, a premium to the prior Nasdaq close.
The deal includes Series D and E warrants, immediate exercisability, and planned use of proceeds for working capital and general corporate purposes.
IceCure (NASDAQ: ICCM) reported a 70% increase in its active U.S. commercial install base of the ProSense® system for breast cancer cryoablation following FDA marketing authorization in October 2025.
Growth is supported by updated ASBrS clinical guidance, higher physician leads at U.S. breast health conferences, and broad media coverage boosting patient awareness.
IceCure Medical (NASDAQ: ICCM) approved a 1-for-30 reverse share split of its ordinary shares to support regaining compliance with Nasdaq’s $1.00 minimum bid price requirement. Shares will begin trading on a split-adjusted basis on June 4, 2026 under the same ticker.
The reverse split, approved at a May 11, 2026 shareholder meeting, will reduce issued and outstanding shares from 84,201,034 to approximately 2,806,701, with no change to authorized share capital of 2.5 billion shares. Fractional shares will be rounded to the nearest whole share, and proportional adjustments will apply to options, warrants and equity plans.
IceCure Medical (NASDAQ:ICCM) reported new ProSense® cryoablation data presented at ECIO 2026. Final ICESECRET kidney cancer results showed 83.9% of patients recurrence-free at 4.0 years, rising to 89.4% for unifocal tumors ≤3 cm, with minimal impact on renal function and short 1.3-day average hospitalization.
Independent breast studies found no residual early-stage breast cancer at 6 and 12 months and 100% excellent cosmetic satisfaction. A fibroadenoma study showed 80.6% median volume reduction at 6 months and 92.9% at 12 months. An overbooked first-ever ECIO breast cryoablation course and prior FDA clearance in early-stage breast cancer support growing clinical interest.
IceCure (Nasdaq: ICCM) received a 180-day Nasdaq extension, until November 9, 2026, to regain compliance with the $1.00 minimum bid price requirement.
The company continues to meet all other Nasdaq Capital Market listing criteria, and its shares remain listed and trading under the symbol ICCM.
IceCure (Nasdaq: ICCM) reported Q1 2026 revenue of $911,000, up 26% year-over-year, driven by North America sales (+84%) and U.S. growth (+31%). Gross profit rose 35% to $295,000 with 32% margin.
Active U.S. ProSense® accounts increased 46% to 19, alongside positive breast and kidney cryoablation clinical data.
IceCure Medical (Nasdaq: ICCM) will report financial and operating results for the three months ended March 31, 2026 on Tuesday, May 12, 2026 before the Nasdaq opens. A conference call and live webcast to discuss results and corporate developments will be held at 11:00 a.m. EDT the same day.
Investors may join by phone (US: 1-888-407-2553; Israel/International: +972-3-918-0696) or via webcast at the company webcast link; a recording will be posted on the investor site.